Efficacy and safety of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis.

J Thorac Dis · 2025 · PMC12688510 · PMID 41376929

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the patient subgroup with baseline EOS ≥300 cells/μL, some efficacy endpoints (e.g., improvement in ACQ-5 scores) did not reach statistical significance, potentially related to insufficient sample size or inherent biological characteristics of this subgroup.

also in 111,027 other papers

showed a trendno p-value reported

Notably, the 75–100 mg dose showed a trend toward improved lung function (FEV1) and quality of life (ACQ-5) while achieving a 61% reduction in SAE risk (HR 0.39, 95% CI: 0.28–0.54) ( 22 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.